Terms: = Uterine cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
739 results:
1. FOXO3a deregulation in uterine smooth muscle tumors.
de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
[TBL] [Abstract] [Full Text] [Related]
2. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Bellone S; Jeong K; Halle MK; Krakstad C; McNamara B; Greenman M; Mutlu L; Demirkiran C; Hartwich TMP; Yang-Hartwich Y; Zipponi M; Buza N; Hui P; Raspagliesi F; Lopez S; Paolini B; Milione M; Perrone E; Scambia G; Altwerger G; Ravaggi A; Bignotti E; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Quick CM; Angioli R; Terranova C; Zaidi S; Nandi S; Alexandrov LB; Siegel ER; Choi J; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2321898121. PubMed ID: 38625939
[TBL] [Abstract] [Full Text] [Related]
3. Establishment and characterization of multiple patient-derived organoids from a case of advanced endometrial cancer.
Maru Y; Kohno M; Suzuka K; Odaka A; Masuda M; Araki A; Itami M; Tanaka N; Hippo Y
Hum Cell; 2024 May; 37(3):840-853. PubMed ID: 38546950
[TBL] [Abstract] [Full Text] [Related]
4. Trichorhinophalangeal Syndrome Type 1 Immunohistochemical Expression in Carcinomas of Gynecologic Origin.
Ruiz F; Tjendra Y; Millan N; Gomez-Fernandez C; Pinto A
Am J Surg Pathol; 2024 May; 48(5):546-550. PubMed ID: 38357982
[TBL] [Abstract] [Full Text] [Related]
5. A phase 2 trial of zanidatamab in her2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Lumish M; Chui MH; Zhou Q; Iasonos A; Sarasohn D; Cohen S; Friedman C; Grisham R; Konner J; Kyi C; Rubinstein M; Troso-Sandoval T; Aghajanian C; Makker V
Gynecol Oncol; 2024 Mar; 182():75-81. PubMed ID: 38262242
[TBL] [Abstract] [Full Text] [Related]
6. Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement.
Kim JH; Kim DY; Kim J; Noh JJ; Hwang WY; Baek MH; Choi MC; Joo WD; Lee YJ; Suh DH; Kim YB
J Gynecol Oncol; 2024 Mar; 35(2):e45. PubMed ID: 38216137
[TBL] [Abstract] [Full Text] [Related]
7. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
8. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
9. Targeting her2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
[TBL] [Abstract] [Full Text] [Related]
10. A rare case of extrarenal Wilms tumor of the uterine corpus: comprehensive genomic profile and review of the literature.
Alessandrini L; Guerriero A; Munari G; Del Forno B; Santoro L; Marchetti M; Nardin M; Tozzi R; Fassan M; Dei Tos AP
Pathologica; 2023 Dec; 115(6):333-340. PubMed ID: 38180141
[TBL] [Abstract] [Full Text] [Related]
11. Antibody-Drug Conjugates in Gynecologic cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract] [Full Text] [Related]
12. Molecular landscape of erbb2/her2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
[TBL] [Abstract] [Full Text] [Related]
13. Decreased her2 expression in endometrial cancer following anti-her2 therapy.
Chui MH; Brown DN; Da Cruz Paula A; da Silva EM; Momeni-Boroujeni A; Reis-Filho JS; Zhang Y; Makker V; Ellenson LH; Weigelt B
J Pathol; 2024 Feb; 262(2):129-136. PubMed ID: 38013631
[TBL] [Abstract] [Full Text] [Related]
14. Characteristics of HPV integration in cervical adenocarcinoma and squamous carcinoma.
Bi Y; Hu J; Zeng L; Chen G; Cai H; Cao H; Ma Q; Wu X
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17973-17986. PubMed ID: 37966613
[TBL] [Abstract] [Full Text] [Related]
15. Mechanism of gemcitabine combined with lobaplatin in interventional treatment of locally advanced cervical cancer.
Lin Y; Yang Q
Anticancer Drugs; 2024 Feb; 35(2):209-217. PubMed ID: 37948339
[TBL] [Abstract] [Full Text] [Related]
16. The value of multiparametric MRI combined with clinical prognostic parameters in predicting the 5-year survival of stage IIIC1 cervical squamous cell carcinoma.
Qin F; Pang H; Ma J; Xu H; Yu T; Luo Y; Dong Y
Eur J Radiol; 2023 Dec; 169():111181. PubMed ID: 37939604
[TBL] [Abstract] [Full Text] [Related]
17. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with her2 expression.
Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
[TBL] [Abstract] [Full Text] [Related]
18. Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma.
Lin S; Sun Y; Cao C; Zhu Z; Xu Y; Liu B; Hu B; Peng T; Zhi W; Xu M; Ding W; Ren F; Ma D; Li G; Wu P
EBioMedicine; 2023 Nov; 97():104846. PubMed ID: 37879219
[TBL] [Abstract] [Full Text] [Related]
19. Invasive stratified mucin-producing carcinoma (ISMC) of the cervix: a clinicopathological and molecular analysis of 59 cases with special emphasis on histogenesis and potential therapeutic targets.
Yao Y; Wang Y; Ye L; Lu B; Lu W
Histopathology; 2024 Jan; 84(2):315-324. PubMed ID: 37735961
[TBL] [Abstract] [Full Text] [Related]
20. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract] [Full Text] [Related]
[Next]
